Literature DB >> 19171113

Atherosclerosis in autoimmune diseases.

Eiji Matsuura1, Kazuko Kobayashi, Luis R Lopez.   

Abstract

Lipid peroxidation occurs frequently in patients with systemic autoimmune diseases and contributes to autoimmune vascular inflammation. Oxidized low-density lipoprotein (oxLDL) interacts with beta2-glycoprotein I (beta2GPI), forming oxLDL/beta2GPI complexes. Circulating oxLDL/beta2GPI complexes and autoantibodies to these complexes have been demonstrated in patients with systemic lupus erythematosus and antiphospholipid syndrome. These findings suggest an immunogenic nature of the complexes and an active proatherogenic role in autoimmunity. Biochemical characterization of the complexes and immunohistochemical studies of atherosclerotic lesions suggest that most of the complexes originate in the arterial wall and are released into circulation. The in vitro macrophage uptake of oxLDL/beta2GPI complexes increased significantly in the presence of antiphospholipid antibodies (anti-beta2GPI), suggesting that macrophage Fcgamma receptors are involved in the lipid intracellular influx that leads to foam cell formation. These findings provide an immunologic explanation for the accelerated development of atherosclerosis seen in systemic lupus erythematosus and antiphospholipid syndrome.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19171113     DOI: 10.1007/s11926-009-0009-1

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  63 in total

Review 1.  Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis.

Authors:  Eiji Matsuura; Kazuko Kobayashi; Masako Tabuchi; Luis R Lopez
Journal:  Prog Lipid Res       Date:  2006-05-30       Impact factor: 16.195

Review 2.  Antiphospholipid antibodies and myocardial infarction.

Authors:  O Vaarala
Journal:  Lupus       Date:  1998       Impact factor: 2.911

3.  Proatherogenic and proinflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL.

Authors:  G Virella; D Atchley; Sinikka Koskinen; D Zheng; Maria F Lopes-Virella
Journal:  Clin Immunol       Date:  2002-10       Impact factor: 3.969

Review 4.  Accelerated atheroma in the antiphospholipid syndrome.

Authors:  Eiji Matsuura; Kazuko Kobayashi; Masako Tabuchi; Luis R Lopez
Journal:  Rheum Dis Clin North Am       Date:  2006-08       Impact factor: 2.670

5.  Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages.

Authors:  Y Hasunuma; E Matsuura; Z Makita; T Katahira; S Nishi; T Koike
Journal:  Clin Exp Immunol       Date:  1997-03       Impact factor: 4.330

Review 6.  Myeloperoxidase-generated oxidants and atherosclerosis.

Authors:  E A Podrez; H M Abu-Soud; S L Hazen
Journal:  Free Radic Biol Med       Date:  2000-06-15       Impact factor: 7.376

7.  Increased levels of serum protein oxidation and correlation with disease activity in systemic lupus erythematosus.

Authors:  Philip E Morgan; Allan D Sturgess; Michael J Davies
Journal:  Arthritis Rheum       Date:  2005-07

Review 8.  Mechanisms of oxidative damage of low density lipoprotein in human atherosclerosis.

Authors:  J W Heinecke
Journal:  Curr Opin Lipidol       Date:  1997-10       Impact factor: 4.776

Review 9.  Autoimmune-mediated atherothrombosis.

Authors:  E Matsuura; L R Lopez
Journal:  Lupus       Date:  2008-10       Impact factor: 2.911

10.  Improved measurement of low-density-lipoprotein susceptibility to copper-induced oxidation: application of a short procedure for isolating low-density lipoprotein.

Authors:  H A Kleinveld; H L Hak-Lemmers; A F Stalenhoef; P N Demacker
Journal:  Clin Chem       Date:  1992-10       Impact factor: 8.327

View more
  11 in total

Review 1.  Natural killer T cells and atherosclerosis: form and function meet pathogenesis.

Authors:  Nicole A Braun; Roman Covarrubias; Amy S Major
Journal:  J Innate Immun       Date:  2010-03-17       Impact factor: 7.349

Review 2.  Dendritic cells, antibodies reactive with oxLDL, and inflammation.

Authors:  J G Tew; M E El Shikh; R M El Sayed; H A Schenkein
Journal:  J Dent Res       Date:  2011-04-29       Impact factor: 6.116

Review 3.  Hyperlipidaemia in paediatric patients: the role of lipid-lowering therapy in clinical practice.

Authors:  Anthony S Wierzbicki; Adie Viljoen
Journal:  Drug Saf       Date:  2010-02-01       Impact factor: 5.606

Review 4.  The multiple faces of RAGE--opportunities for therapeutic intervention in aging and chronic disease.

Authors:  Ravichandran Ramasamy; Alexander Shekhtman; Ann Marie Schmidt
Journal:  Expert Opin Ther Targets       Date:  2015-11-11       Impact factor: 6.902

5.  Analysis of Drug Effects on Primary Human Coronary Artery Endothelial Cells Activated by Serum Amyloid A.

Authors:  K Lakota; D Hrušovar; M Ogrič; K Mrak-Poljšak; S Čučnik; M Tomšič; B Božič; P Žigon; S Sodin-Semrl
Journal:  Mediators Inflamm       Date:  2018-02-13       Impact factor: 4.711

Review 6.  Therapeutic Potential and Immunomodulatory Role of Coenzyme Q10 and Its Analogues in Systemic Autoimmune Diseases.

Authors:  Chary López-Pedrera; José Manuel Villalba; Alejandra Mª Patiño-Trives; Maria Luque-Tévar; Nuria Barbarroja; Mª Ángeles Aguirre; Alejandro Escudero-Contreras; Carlos Pérez-Sánchez
Journal:  Antioxidants (Basel)       Date:  2021-04-13

7.  Association of serum levels of antibodies against ALDOA and FH4 with transient ischemic attack and cerebral infarction.

Authors:  Hao Wang; Hao Lu; Xiao-Meng Zhang; Ken-Ichiro Goto; Eiichi Kobayashi; Yoichi Yoshida; Akihiko Adachi; Tomoo Matsutani; Yasuo Iwadate; Seiichiro Mine; Toshio Machida; Mizuki Sata; Kazumasa Yamagishi; Hiroyasu Iso; Norie Sawada; Shoichiro Tsugane; Ikuo Kamitsukasa; Takeshi Wada; Akiyo Aotsuka; Kazuo Sugimoto; Hirotaka Takizawa; Koichi Kashiwado; Hideo Shin; Go Tomiyoshi; Rika Nakamura; Natsuko Shinmen; Hideyuki Kuroda; Anding Xu; Takaki Hiwasa
Journal:  BMC Neurol       Date:  2021-07-09       Impact factor: 2.474

8.  The association among antioxidant enzymes, autoantibodies, and disease severity score in systemic lupus erythematosus: comparison of neuropsychiatric and nonneuropsychiatric groups.

Authors:  Yu-Jih Su; Tien-Tsai Cheng; Chung-Jen Chen; Wen-Chan Chiu; Wen-Neng Chang; Nai-Wen Tsai; Chia-Te Kung; Wei-Che Lin; Chih-Cheng Huang; Ya-Ting Chang; Chih-Min Su; Yi-Fang Chiang; Ben-Chung Cheng; Cheng-Hsien Lu
Journal:  Biomed Res Int       Date:  2014-04-27       Impact factor: 3.411

9.  Simvastatin Efficiently Lowers Small LDL-IgG Immune Complex Levels: A Therapeutic Quality beyond the Lipid-Lowering Effect.

Authors:  Gerd Hörl; Harald Froehlich; Ulrika Ferstl; Gerhard Ledinski; Josepha Binder; Gerhard Cvirn; Tatjana Stojakovic; Michael Trauner; Christoph Koidl; Erwin Tafeit; Karin Amrein; Hubert Scharnagl; Günther Jürgens; Seth Hallström
Journal:  PLoS One       Date:  2016-02-03       Impact factor: 3.240

10.  LDLR and PCSK9 Are Associated with the Presence of Antiphospholipid Antibodies and the Development of Thrombosis in aPLA Carriers.

Authors:  Eguzkine Ochoa; Mikel Iriondo; Carmen Manzano; Asier Fullaondo; Irama Villar; Guillermo Ruiz-Irastorza; Ana M Zubiaga; Andone Estonba
Journal:  PLoS One       Date:  2016-01-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.